Liang Zeng

ORCID: 0000-0002-4517-7470
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Management of metastatic bone disease
  • Spine and Intervertebral Disc Pathology
  • Cancer Diagnosis and Treatment
  • Cancer survivorship and care
  • Brain Metastases and Treatment
  • Palliative Care and End-of-Life Issues
  • Lung Cancer Treatments and Mutations
  • Spinal Fractures and Fixation Techniques
  • Bone health and treatments
  • Advanced Radiotherapy Techniques
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Glioma Diagnosis and Treatment
  • Healthcare and Venom Research
  • Head and Neck Cancer Studies
  • Medical Imaging Techniques and Applications
  • Prostate Cancer Diagnosis and Treatment
  • Acupuncture Treatment Research Studies
  • Immunotherapy and Immune Responses
  • Lung Cancer Diagnosis and Treatment
  • Sleep and related disorders
  • NF-κB Signaling Pathways
  • RNA modifications and cancer
  • CAR-T cell therapy research
  • Nausea and vomiting management

Central South University
2013-2025

Hunan Cancer Hospital
2012-2025

Guangzhou Medical University
2018-2024

Guangzhou Women and Children Medical Center
2018-2024

Xiamen University of Technology
2024

Wuhan YZY Biopharma (China)
2021-2023

Royal Victoria Regional Health Centre
2023

Third Xiangya Hospital
2021-2023

Shanghai Medical College of Fudan University
2022-2023

Sunnybrook Health Science Centre
2010-2022

Recently, therapeutic antibodies against programmed cell death 1 (PD-1) and its ligand (PD-L1) have exerted potent anticancer effect in a variety of tumors. However, blocking the PD-1/PD-L1 axis alone is not sufficient to restore normal immune response. Other negative regulators antitumor immunity, like TGF-β VEGFA, are also involved escape tumor cells induce immunotherapy resistance.We developed novel anti-TGF-β/VEGF bispecific antibody Y332D based on Nano-YBODY™ technology platform. The...

10.1186/s13045-023-01487-5 article EN cc-by Journal of Hematology & Oncology 2023-08-12

Heterobifunctional molecules have proven powerful tools to induce ligase-dependent ubiquitination of target proteins. We describe here a chemical strategy for controlling different post-translational modification (PTM): phosphorylation. were designed promote the proximity protein phosphatase (PP1) targets. The synthesized induced PP1-dependent dephosphorylation AKT and EGFR. To our knowledge, this work represents first examples small recruiting non-native partners removal PTM.

10.1021/acs.jmedchem.9b01167 article EN Journal of Medicinal Chemistry 2019-12-24

The outbreak of 2019 novel coronavirus (2019-nCoV) pneumonia was reported in Wuhan, Hubei Province, China December and has spread internationally. This article discusses how radiology departments can most effectively respond to this public health emergency. On January 31, 2020, the World Health Organization declared a new as "Public Emergency International Concern (PHEIC)." February 13, officially named 2019-nCoV Corona Virus Disease-2019 Geneva, Switzerland. virus rapidly various cities...

10.1016/j.acra.2020.02.003 article EN other-oa Academic Radiology 2020-02-26

The most recent systematic review of randomized trials in patients with bone metastases has shown equal efficacy single fraction (SF) and multiple (MF) palliative radiation therapy pain relief. It is important to determine the patient population which evidence applies. This study aims examine eligibility criteria studies included define characteristics "uncomplicated" metastases. Inclusion exclusion 21 were compared. Common documented hopes defining specific features a common representative...

10.1016/j.jbo.2014.12.001 article EN cc-by-nc-nd Journal of bone oncology 2015-01-23

Abstract Nasopharyngeal carcinoma (NPC) has the highest rate of metastasis among head and neck cancers, distant is major reason for treatment failure. We have previously shown that high cyclooxygenase‐2 (COX‐2) expression associated with a poor prognosis patients NPC inhibits chemotherapy‐induced senescence in cells. In this study, we found COX‐2 was upregulated cancer‐associated fibroblasts (CAFs) derived from by RNA‐Seq. Furthermore, elevated CAF detected survival using...

10.1002/mc.23150 article EN cc-by Molecular Carcinogenesis 2019-12-22

Rationale: Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults.Radiotherapy has long been an important treatment for GBM.Despite recent advances radiotherapy, prognosis of GBM remains poor due to radioresistance.Autophagy reported as a basic factor prolong survival under radiation stress, but molecular mechanism how autophagy contributes radioresistance was still lacking.Methods: We established radioresistant cells identified their protein profiles by Tandem...

10.7150/thno.81999 article EN cc-by Theranostics 2023-01-01

Abstract Background Pembrolizumab has been indicated in the treatment of solid tumors with high frequency microsatellite instability (MSI-H) or tumor mutational burden (TMB-H); however, real-world data on effectiveness pembrolizumab without chemotherapy this molecular subset remain limited. Our retrospective study evaluated clinical efficacy and safety treating advanced either MSI-H TMB-H. Methods This analyzed from 116 patients TMB-H cancers who received regardless setting. We objective...

10.1007/s00262-024-03660-2 article EN cc-by Cancer Immunology Immunotherapy 2024-03-07

Radiotherapy combined with immune checkpoint blockade has gradually revealed the superiority in antitumor therapy; however, contribution of host PD-L1 remains elusive. In this study, we found that activation CD8+ T cells was strikingly increased both irradiated PD-L1-expressing primary tumor and distant non-irradiated syngeneic PD-L1-deficient mouse host, thus enhanced radiation-induced abscopal effect (ATAE) by activating cGAS-STING pathway. Notably, autophagy inhibitors distinctively...

10.1016/j.isci.2022.104690 article EN cc-by iScience 2022-06-30

Background: Few studies incorporate patient self-assessment scales in prognostic models of survival prediction. The Edmonton Symptom Assessment Scale (ESAS) is commonly used as a symptom screening tool cancer patients. Objective: goal this study was to evaluate the value ESAS for prediction advanced population. Materials and Methods: Patients completed demographic information prior palliative radiotherapy consultation at follow-up Odette Cancer Centre between 1999 2009. Generalized...

10.1089/jpm.2010.0438 article EN Journal of Palliative Medicine 2011-01-21

Resistance to radiotherapy and chemotherapy currently represents one of the major reasons for therapeutic failure in nasopharyngeal carcinoma (NPC). However, mechanisms underlying resistance NPC remain unclear. In this study, cell counting assay, cycle assay senescence associated β-galactosidase activity were performed evaluate growth, proliferation senescence, respectively. We found that aberrant expression cyclooxygenase-2 (COX-2) was with a poor outcome recurrance patients NPC. cells,...

10.3892/ijo.2018.4462 article EN cc-by-nc-nd International Journal of Oncology 2018-06-29

Objective: This study was conducted for investigating the functions of circular RNA circRNA_100146 (circRNA_100146) in development prostate cancer (PCa) and identifying underlying mechanisms circRNA_100146/miR-615-5p/TRIP13 axis. Materials Methods: Under support RT-PCR, expression PCa cells examined. Cell Counting Kit-8 (CCK-8) assays clone formation were applied to assessment cell proliferation. We then determined invasion migration through transwell wound healing assays. pull-down...

10.3389/fmolb.2021.693477 article EN cc-by Frontiers in Molecular Biosciences 2021-07-07

Abstract The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. ultimate approach end is timely application vaccines achieve herd immunity. Here, novel receptor-binding domain (RBD) homodimer was developed as vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents non-human primates, protected mice from challenge...

10.1038/s41421-021-00320-y article EN cc-by Cell Discovery 2021-09-07
Coming Soon ...